These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25424849)

  • 1. Molecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage response.
    Grabocka E; Commisso C; Bar-Sagi D
    Clin Cancer Res; 2015 Mar; 21(6):1243-7. PubMed ID: 25424849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.
    Grabocka E; Pylayeva-Gupta Y; Jones MJ; Lubkov V; Yemanaberhan E; Taylor L; Jeng HH; Bar-Sagi D
    Cancer Cell; 2014 Feb; 25(2):243-56. PubMed ID: 24525237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
    Smith J; Tho LM; Xu N; Gillespie DA
    Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance.
    Ray-David H; Romeo Y; Lavoie G; Déléris P; Tcherkezian J; Galan JA; Roux PP
    Oncogene; 2013 Sep; 32(38):4480-9. PubMed ID: 23108403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
    Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
    Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Pathways: Targeting ATR in Cancer Therapy.
    Karnitz LM; Zou L
    Clin Cancer Res; 2015 Nov; 21(21):4780-5. PubMed ID: 26362996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability.
    Menoyo A; Alazzouzi H; Espín E; Armengol M; Yamamoto H; Schwartz S
    Cancer Res; 2001 Nov; 61(21):7727-30. PubMed ID: 11691784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into checkpoint kinase 1 in the DNA damage response signaling network.
    Dai Y; Grant S
    Clin Cancer Res; 2010 Jan; 16(2):376-83. PubMed ID: 20068082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATR-CHK1-E2F3 signaling transactivates human ribonucleotide reductase small subunit M2 for DNA repair induced by the chemical carcinogen MNNG.
    Gong C; Liu H; Song R; Zhong T; Lou M; Wang T; Qi H; Shen J; Zhu L; Shao J
    Biochim Biophys Acta; 2016 Apr; 1859(4):612-26. PubMed ID: 26921499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Dependencies in RAS-Driven Cancers.
    Kimmelman AC
    Clin Cancer Res; 2015 Apr; 21(8):1828-34. PubMed ID: 25878364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of ATRIP protein abundance by RAD9 in the DNA damage repair pathway.
    Peng XJ; Liu SJ; Bao CM; Liu YZ; Xie HW; Cai YH; Li BM; Hang HY; Ding X
    Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):31-6. PubMed ID: 26667770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA REPAIR. Drugging DNA repair.
    Jackson SP; Helleday T
    Science; 2016 Jun; 352(6290):1178-9. PubMed ID: 27257245
    [No Abstract]   [Full Text] [Related]  

  • 14. DNA damage checkpoint, damage repair, and genome stability.
    Liu WF; Yu SS; Chen GJ; Li YZ
    Yi Chuan Xue Bao; 2006 May; 33(5):381-90. PubMed ID: 16722332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical strategies for development of ATR inhibitors.
    Llona-Minguez S; Höglund A; Jacques SA; Koolmeister T; Helleday T
    Expert Rev Mol Med; 2014 May; 16():e10. PubMed ID: 24810715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cell cycle, mitosis and therapeutic applications].
    Levy A; Albiges-Sauvin L; Massard C; Soria JC; Deutsch E
    Bull Cancer; 2011 Oct; 98(9):1037-45. PubMed ID: 21669563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATR/Chk1/Smurf1 pathway determines cell fate after DNA damage by controlling RhoB abundance.
    Wang M; Guo L; Wu Q; Zeng T; Lin Q; Qiao Y; Wang Q; Liu M; Zhang X; Ren L; Zhang S; Pei Y; Yin Z; Ding F; Wang HR
    Nat Commun; 2014 Sep; 5():4901. PubMed ID: 25249323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
    Lv J; Wang J; Chang S; Liu M; Pang X
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATR inhibition preferentially targets homologous recombination-deficient tumor cells.
    Krajewska M; Fehrmann RS; Schoonen PM; Labib S; de Vries EG; Franke L; van Vugt MA
    Oncogene; 2015 Jun; 34(26):3474-81. PubMed ID: 25174396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma.
    Weng MT; Tung TH; Lee JH; Wei SC; Lin HL; Huang YJ; Wong JM; Luo J; Sheu JC
    Sci Rep; 2015 Apr; 5():9357. PubMed ID: 25880358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.